Chemistry and pharmacology of GABA B receptor ligands

Advances in Pharmacology

Volumn 58, Issue C, 2010, Pages 19-62

  Froestl, Wolfgang ^a  

^a AC IMMUNE SA   (Switzerland)

Author keywords

Agonists; Antagonists; Partial agonists; Positive allosteric modulators; Radioligands

Indexed keywords

2 HYDROXY SACLOFEN; 2,6 DI TERT BUTYL 4 (3 HYDROXY 2,2 DIMETHYLPROPYL)PHENOL; 3 AMINOPROPANEPHOSPHINIC ACID; 3 AMINOPROPYL(DIETHOXYMETHYL)PHOSPHINIC ACID; 3 AMINOPROPYL(METHYL)PHOSPHINIC ACID; 3 AMINOPROPYLBUTYLPHOSPHINIC ACID; 3 [1 [3 [(CYCLOHEXYLMETHYL)HYDROXYPHOSPHINYL] 2 HYDROXYPROPYLAMINO]ETHYL]BENZOIC ACID; 3 [1 [[2 HYDROXY 3 [HYDROXY(4 METHOXYBENZYL)PHOSPHINYL]PROPYL]AMINO]ETHYL]BENZOIC ACID; 4 AMINO 3 PHENYLBUTYRIC ACID; 4 AMINOBUTYRIC ACID B RECEPTOR; 4 AMINOBUTYRIC ACID B RECEPTOR BLOCKING AGENT; 4 AMINOBUTYRIC ACID B RECEPTOR STIMULATING AGENT; 5,5 DIMETHYL 2 MORPHOLINEACETIC ACID; ANXIOLYTIC AGENT; ARBACLOFEN PLACARBIL; AZD 3355; BACLOFEN; BENZYL[3 [[1 (3,4 DICHLOROPHENYL)ETHYL]AMINO] 2 HYDROXYPROPYL]PHOSPHINIC ACID; CGP 44532; CGP 46381; CGP 51176; CGP 54626; CGP 55176; CGP 63360; GABAPENTIN; LESOGABARAN; N,N' DICYCLOPENTYL 2 METHYLTHIO 5 NITRO 4,6 PYRIMIDINEDIAMINE; NVP BHF 177; OXYBATE SODIUM; PHACLOFEN; UNCLASSIFIED DRUG; UNINDEXED DRUG; XP 19986; [3 (3,4 DICHLOROBENZYLAMINO)PROPYL](DIETHOXYMETHYL)PHOSPHINIC ACID; 4 AMINOBUTYRIC ACID RECEPTOR BLOCKING AGENT; 4 AMINOBUTYRIC ACID RECEPTOR STIMULATING AGENT; LIGAND;

ABSENCE; ALCOHOL ABUSE; ALCOHOLISM; ANALGESIA; ANTICONVULSANT ACTIVITY; ARTICLE; CATAPLEXY; CENTRAL NERVOUS SYSTEM DISEASE; CEREBRAL PALSY; CLINICAL TRIAL; CLUSTER HEADACHE; COCAINE DEPENDENCE; DAYTIME SOMNOLENCE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CEREBROSPINAL FLUID LEVEL; DRUG MECHANISM; DRUG MEGADOSE; DRUG METABOLISM; DRUG PENETRATION; DRUG POTENTIATION; DRUG STRUCTURE; DRUG SYNTHESIS; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL SYMPTOM; GENERALIZED EPILEPSY; HEMIPLEGIA; HEROIN DEPENDENCE; HICCUP; HUMAN; HYPERALGESIA; MIGRAINE; MORPHINE ADDICTION; MULTIPLE SCLEROSIS; NEUROPATHY; NONHUMAN; POSTTRAUMATIC STRESS DISORDER; PRIORITY JOURNAL; QUADRIPLEGIA; RACEMIC MIXTURE; RECEPTOR DOWN REGULATION; STIFF MAN SYNDROME; TETANUS; TOBACCO DEPENDENCE; TRANQUILIZING ACTIVITY; TRIGEMINUS NEURALGIA; VISCERAL PAIN; WITHDRAWAL SYNDROME; WORKING MEMORY; ALLOSTERISM; ANIMAL; CHEMISTRY; DRUG ANTAGONISM; DRUG EFFECT; METABOLISM;

ALLOSTERIC REGULATION; ANIMALS; GABA AGONISTS; GABA ANTAGONISTS; HUMANS; LIGANDS; RECEPTORS, GABA-B;

EID: 77955068362     PISSN: 10543589     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S1054-3589(10)58002-5     Document Type: Chapter

References (350)

1. B receptor. CNS Drug Reviews 2007, 13:308-316.
2. Addolorato G., Caputo F., Capristo E., et al. Ability of baclofen in reducing alcohol craving and intake: II-preliminary clinical evidence. Alcoholism, Clinical and Experimental Research 2000, 24:67-71.
3. Addolorato G., Caputo F., Capristo E., et al. Rapid suppression of alcohol withdrawal syndrome by baclofen. American Journal of Medicine 2002, 112:226-229.
4. Addolorato G., Caputo F., Capristo E., et al. Baclofen efficacy in reducing alcohol craving and intake: A preliminary double-blind randomized controlled study. Alcohol and Alcoholism 2002, 37:504-508.
5. Addolorato G., Leggio L., Abenavoli L., et al. Suppression of alcohol delirium tremens by baclofen administration: A case report. Clinical Neuropharmacology 2003, 26:258-262.
6. Addolorato G., Leggio L., Abenavoli L., et al. Baclofen for outpatient treatment of alcohol withdrawal syndrome. Journal of Family Practice 2005, 54:24.
7. Addolorato G., Leggio L., Abenavoli L., et al. Baclofen in the treatment of alcohol withdrawal syndrome: A comparative study vs diazepam. American Journal of Medicine 2006, 119:276-278.
8. Addolorato G., Leggio L., Agabio R., et al. Baclofen: A new drug for the treatment of alcohol dependence. International Journal of Clinical Practice 2006, 60:1003-1008.
9. B receptor system in alcoholism and stress: Focus on clinical studies and treatment perspectives. Alcohol 2009, 43:559-563.
10. Addolorato G., Leggio L., Ferrulli A., et al. Effectiveness and safety of baclofen for maintenance of alcohol abstinence in alcohol-dependent patients with liver cirrhosis: A randomized, double-blind study. Lancet 2007, 370:1915-1922.
11. Aizawa M., Ito Y., Fukuda H. Pharmacological profiles of generalized absence seizures in lethargic, stargazer and γ-hydroxybutyrate-treated model mice. Neuroscience Research 1997, 29:17-25.
12. Akhondzadeh S., Ahmadi-Abhari S.A., Assadi S.M., et al. Double-blind randomized controlled trial of baclofen vs. clonidine in the treatment of opiates withdrawal. Journal of Clinical Pharmacy and Therapeutics 2000, 25:347-353.
13. B positive allosteric modulator (R,S)-5,7-di-tert-butyl-3-hydroxy-3-trifluoromethyl-3 H-benzofuran-2-one. Synthetic Communications 2008, 38:3398-3405.
14. Allan R.D., Bates M.C., Drew C.A., et al. A new synthesis, resolution and in vitro activities of (R)- and (S)-Β-phenyl-GABA. Tetrahedron 1990, 46:2511-2524.
15. B ) receptor agonists as gastroesophageal reflux inhibitors. Journal of Medicinal Chemistry 2008, 51:4315-4320.
16. 3 H]-dopamine release from rat ventral tegmental area in vitro after chronic nicotine administration. BMC Pharmacology 2004, 4:24.
17. 3 H]CGP62349 binding in the Rhesus monkey thalamus and basal ganglia and the influence of lesions in the reticular thalamic nucleus. Neuroscience 1999, 93:1339-1347.
18. Andrén P.E., Emmett M.R., DaGue B.B., et al. Blood-brain barrier penetration of 3-aminopropyl-n-butylphosphinic acid (CGP 36742) in rat brain by microdialysis/mass spectrometry. Journal of Mass Spectrometry 1998, 33:281-287.
19. Andriamampandry C., Taleb O., Kemmel V., et al. Cloning and functional characterization of a γ-hydroxybutyrate receptor identified in the human brain. FASEB Journal 2007, 21:885-895.
20. Audus K.L., Borchardt R.T. Characteristics of the large neutral amino acid transport system of bovine brain microvessel endothelial cell monolayers. Journal of Neurochemistry 1986, 47:484-488.
21. Baker K.A., Taylor J.W., Lilly G.E. Treatment of trigeminal neuralgia: Use of baclofen in combination with carbamazepine. Clinical Pharmacy 1985, 4:93-96.
22. B agonist reverses the behavioral sensitization to morphine in rats. Psychopharmacology 2007, 192:79-85.
23. Baylis E.K., Campbell C.D., Dingwall J.G. 1-Aminophosphonous acids. Part 1. Isosteres of the protein amino acids. Journal of the Chemical Society. Perkin Transactions 1984, 1:2845-2853.
24. Becker R., Alberti O., Bauer B.L. Continuous intrathecal baclofen infusion in severe spasticity after traumatic or hypoxic brain injury. Journal of Neurology 1997, 244:160-166.
25. Becker W.J., Harris C.J., Long M.L., et al. Long-term intrathecal baclofen therapy in patients with intractable spasticity. Canadian Journal of Neurological Sciences 1995, 22(3):208-217.
26. B receptor forms. Bioorganic & Medicinal Chemistry 1999, 7:2697-2704.
27. Bernasconi R., Mathivet P., Bischoff S., Marescaux C. γ-Hydroxy-butyric acid: An endogenous neuromodulator with abuse potential?. Trends in Pharmacological Sciences 1999, 20:135-141.
28. Bertrand S., Morin F., Lacaille J.C. Different actions of gabapentin and baclofen in hippocampus from weaver mice. Hippocampus 2003, 13:525-528.
29. Bertrand S., Ng G.Y., Purisai M.G., et al. The anticonvulsant, antihyperalgesic agent gabapentin is an agonist at brain gamma-aminobutyric acid type B receptors negatively coupled to voltage-dependent calcium channels. Journal of Pharmacology and Experimental Therapeutics 2001, 298:15-24.
30. B receptors in hippocampal pyramidal cells. Synapse 2003, 50:95-109.
31. B receptors. Physiological Reviews 2004, 84:835-867.
32. B receptor agonist baclofen. Life Sciences 2001, 70:395-401.
33. B receptor. Journal of Biological Chemistry 2004, 279:29085-29091.
34. B receptors. Pharmacology Communications 1992, 2:23.
35. B receptors (Abstract). European Journal of Neuroscience 1988, 16(Suppl.):10.
36. B receptor antagonist radioligand. Pharmacology Reviews and Communications 1996, 8:97-98.
37. Blackshaw L.A., Staunton E., Lehmann A., et al. Inhibition of transient LES relaxations and reflux in ferrets by GABA receptor agonists. American Journal of Physiology 1999, 277(4 Pt 1):G867-G874.
38. B receptor agonist CGP44532 (3-amino-2-hydroxypropylmethylphosphinic acid) in rat plasma after pre-column derivatization by micro-high-performance liquid chromatography combined with negative tandem mass spectrometry. Journal of Chromatography. B, Biomedical Sciences and Applications 2000, 748:349-359.
39. Bolser D.C., Blythin D.J., Chapman R.W., et al. The pharmacology of SCH 50911: A novel, orally-active GABA-beta receptor antagonist. Journal of Pharmacology and Experimental Therapeutics 1995, 274:1393-1398.
40. B antagonist endowed with cognition enhancing activity. Neuropharmacology 1999, 38:1789-1795.
41. Boots R.J., Lipman J., O'Callaghan J., et al. The treatment of tetanus with intrathecal baclofen. Anaesthesia and Intensive Care 2000, 28:438-442.
42. Bowery N.G. Baclofen: 10 years on. Trends in Pharmacological Sciences 1982, 3:400-403.
43. B receptor: A site of therapeutic benefit. Current Opinion in Pharmacology 2006, 6:37-43.
44. Bowery N.G., Hill D.R., Hudson A.L., et al. (-)-Baclofen decreases neurotransmitter release in the mammalian CNS by an action at a novel GABA receptor. Nature 1980, 283(5742):92-94.
45. Brar S.P., Smith M.B., Nelson L.M., et al. Evaluation of treatment protocols on minimal to moderate spasticity in multiple sclerosis. Archives of Physical Medicine and Rehabilitation 1991, 72:186-189.
46. B agonist CGP 44532 decreases cocaine self-administration in rats: Demonstration using a progressive ratio and a discrete trials procedure. Neuropharmacology 1999, 38:1797-1804.
47. B antagonist CGP56433A attenuates the effect of baclofen on cocaine but not heroin self-administration in the rat. Psychopharmacology 2002, 160:49-55.
48. B agonist for the potential treatment of gastro-esophageal reflux disease. IDrugs 2009, 12:576-584.
49. Breslow M.F., Fankhauser M.P., Potter R.L., et al. Role of γ-amino-butyric acid in antipanic drug efficacy. American Journal of Psychiatry 1989, 146:353-356.
50. Brightwell J.J., Gallagher M., Colombo P.J. Hippocampal CREB1 but not CREB2 is decreased in aged rats with spatial memory impairment. Neurobiology of Learning and Memory 2004, 81:19-26.
51. Brogden R.N., Speight T.M., Avery G.S. Baclofen: A preliminary report of its pharmacological properties and therapeutic efficacy in spasticity. Drugs 1974, 8:1-14.
52. B receptor agonist, baclofen, and the positive allosteric modulator, CGP7930, inhibit visceral pain-related responses to colorectal distension in rats. Neuropharmacology 2009, 56:362-367.
53. Buonaguro V., Scelsa B., Curci D., et al. Epilepsy and intrathecal baclofen therapy in children with cerebral palsy. Pediatric Neurology 2005, 33:110-113.
54. Cange L., Johnsson E., Rydholm H., et al. Baclofen-mediated gastro-oesophageal acid reflux control in patients with established reflux disease. Alimentary Pharmacology & Therapeutics 2002, 16:869-873.
55. B receptor antagonist, SCH 50911, in rats undergoing ethanol withdrawal syndrome. European Journal of Pharmacology 2002, 445:195-199.
56. B receptor antagonist, SCH 50911, of γ-hydroxybutyric acid-induced mortality in mice. European Journal of Pharmacology 2004, 503:77-80.
57. Carai M.A., Colombo G., Gessa G.L. Resuscitative effect of a γ-aminobutyric acid B receptor antagonist on γ-hydroxybutyric acid mortality in mice. Annals of Emergency Medicine 2005, 45:614-619.
58. B receptor. European Journal of Pharmacology 2004, 504:213-216.
59. B )-receptor mediation of different in vivo effects of γ-butyrolactone. Journal of Pharmacological Sciences 2008, 106:199-207.
60. Cates L.A. Anticonvulsant phosphorus analogs of GABA. Drug Development Research 1985, 5:395-399.
61. Chang C.H., Yang D.S., Yoo C.S., et al. Structure and absolute configuration of (R)-baclofen monochloride. Acta Crystallographica 1982, B38:2065-2067.
62. B inhibition of cholinergic and peptidergic bronchoconstriction in guinea pigs: Studies with new agonists and antagonists. Pharmacology 1993, 46:315-323.
63. C antagonists inhibit myopia development and facilitate learning and memory. Journal of Pharmacology and Experimental Therapeutics 2009, 328:448-457.
64. C receptor antagonists differentiate between human rho1 and rho2 receptors expressed in Xenopus oocytes. European Journal of Pharmacology 1998, 357:227-234.
65. C receptor antagonists. European Journal of Pharmacology 1997, 329:223-229.
66. B receptor allosteric potentiator 2,6-di-tert-butyl-4-(3-hydroxy-2,2-dimethylpropyl)-phenol (CGP7930) of synaptic transmission in the rat hippocampal CA1 area. Journal of Pharmacology and Experimental Therapeutics 2006, 317:1170-1177.
67. B receptor modulators potentiate baclofen-induced depression of dopamine neuron activity in the rat ventral tegmental area. British Journal of Pharmacology 2005, 144:926-932.
68. B receptors?. Journal of Biomedical Science 2004, 11(3):346-355.
69. B receptor in alcohol dependence: Reducing effect of baclofen on alcohol intake and alcohol motivational properties in rats and amelioration of alcohol withdrawal syndrome and alcohol craving in human alcoholics. Neurotoxicity Research 2004, 6:403-414.
70. B receptor inhibition causes locomotor stimulation in mice. European Journal of Pharmacology 2001, 433:101-104.
71. B receptor agonists baclofen and CGP44532 prevent acquisition of alcohol drinking behaviour in alcohol-preferring rats. Alcohol and Alcoholism 2002, 37:499-503.
72. Colombo G., Serra S., Vacca G., et al. Baclofen-induced suppression of alcohol deprivation effect in Sardinian alcohol-preferring (sP) rats exposed to different alcohol concentrations. European Journal of Pharmacology 2006, 550:123-126.
73. B receptor agonists for the treatment of drug addiction: A review of recent findings. Drug and Alcohol Dependence 2002, 65:209-220.
74. Crunelli V., Emri Z., Leresche N. Unravelling the brain targets of γ-hydroxybutyric acid. Current Opinion in Pharmacology 2006, 6:44-52.
75. B receptors in anxiety and depression. Trends in Pharmacological Sciences 2005, 26:36-43.
76. B receptor-positive modulator GS39783 (N,N'-dicyclopentyl-2-methylsulfanyl-5-nitro-pyrimidine-4,6-diamine): Anxiolytic-like activity without side effects associated with baclofen or benzodiazepines. Journal of Pharmacology and Experimental Therapeutics 2004, 310:952-963.
77. Dambrova M., Zvejniece L., Liepinsh E., et al. Comparative pharmacological activity of optical isomers of phenibut. European Journal of Pharmacology 2008, 583:128-134.
78. Deguchi Y., Inabe K., Tomiyasu K., et al. Study on brain interstitial fluid distribution and blood-brain barrier transport of baclofen in rats by microdialysis. Pharmaceutical Research 1995, 12:1838-1844.
79. B receptor-mediated effects in human and rat neocortical neurones in vitro. Neuropharmacology 1999, 38:1755-1766.
80. Demazière J., Saissy J.M., Vitris M., et al. Intermittent intrathecal baclofen for severe tetanus. Lancet 1991, 337(8738):427.
81. B1b receptor. Biochemical Journal 2005, 386(Pt 3):423-431.
82. C receptor antagonist on sleep-waking cycle in the rat. European Journal of Pharmacology 2006, 535:177-181.
83. Dicpinigaitis P.V., Dobkin J.B. Antitussive effect of the GABA-agonist baclofen. Chest 1997, 111:996-999.
84. Dicpinigaitis P.V., Grimm D.R., Lesser M. Baclofen-induced cough suppression in cervical spinal cord injury. Archives of Physical Medicine and Rehabilitation 2000, 81:921-923.
85. Dicpinigaitis P.V., Rauf K. Treatment of chronic, refractory cough with baclofen. Respiration 1998, 65:86-88.
86. Dingwall J.G., Ehrenfreund J., Hall R.G., et al. Synthesis of γ-aminopropylphosphonous acids using hypophosphorous acid synthons. Phosphorus, Sulfur, and Silicon and the Related Elements 1987, 30:571-574.
87. B receptor agonist, is hedonically neutral and reduces cocaine-induced enhancement of reward. Neuropharmacology 2002, 42:626-632.
88. Drake R.G., Davis L.L., Cates M.E., et al. Baclofen treatment for chronic posttraumatic stress disorder. Annals of Pharmacotherapy 2003, 37:1177-1181.
89. Dralle D., Müller H., Zierski J., et al. Intrathecal baclofen for spasticity. Lancet 1985, 326(8462):1003.
90. B1 subunit. Molecular Pharmacology 2006, 70:2027-2036.
91. B receptors in the central nervous system. Nature 1988, 332(6160):156-158.
92. Engrand N., Benhamou D. About intrathecal baclofen in tetanus. Anaesthesia and Intensive Care 2001, 29:306-307.
93. Engrand N., Guerot E., Rouamba A., et al. The efficacy of intrathecal baclofen in severe tetanus. Anesthesiology 1999, 90:1773-1776.
94. B receptor alterations as indicators of physiological and pharmacological function. Biochemical Pharmacology 2004, 68:1541-1548.
95. B receptor agonists. Life Sciences 1998, 62:1525-1530.
96. Enna S.J., McCarson K.E. The role of GABA in the mediation and perception of pain. Advances in Pharmacology 2006, 54:1-27.
97. B receptor antagonist, enhances expression of brain-derived neurotrophic factor and attenuates dopamine depletion in the rat corpus striatum following a 6-hydroxydopamine lesion of the nigrostriatal pathway. Neuroscience Letters 2006, 406:102-106.
98. B -receptor antagonist SCH 50911. Journal of Neural Transmission 1999, 106:383-394.
99. Evans S.M., Bisaga A. Acute interaction of baclofen in combination with alcohol in heavy social drinkers. Alcoholism, Clinical and Experimental Research 2009, 33:19-30.
100. Fadda P., Scherma M., Fresu A., et al. Baclofen antagonizes nicotine-, cocaine-, and morphine-induced dopamine release in the nucleus accumbens of rat. Synapse 2003, 50:1-6.
101. Fattore L., Spano M.S., Cossu G., et al. Baclofen prevents drug-induced reinstatement of extinguished nicotine-seeking behaviour and nicotine place preference in rodents. European Neuropsychopharmacology 2009, 19:487-498.
102. B -mediated inhibitory postsynaptic transmission on rat midbrain dopaminergic neurons by facilitating GIRK currents. European Journal of Neuroscience 2009, 29:1369-1377.
103. File S.E., Mabbutt P.S., Andrews N. Diazepam withdrawal responses measured in the social interaction test of anxiety and their reversal by baclofen. Psychopharmacology 1991, 104:62-66.
104. B receptor agents on cocaine priming, discrete contextual cue and food induced relapses. European Journal of Pharmacology 2007, 571:166-173.
105. B receptors in drug addiction. Pharmacological Reports 2008, 60:755-770.
106. B receptor antagonist, agonists and allosteric positive modulator on the cocaine-induced self-administration and drug discrimination. European Journal of Pharmacology 2007, 574:148-157.
107. Flannery B.A., Garbutt J.C., Cody M.W., et al. Baclofen for alcohol dependence: A preliminary open-label study. Alcoholism, Clinical and Experimental Research 2004, 28:1517-1523.
108. B agonist baclofen reduces cigarette consumption in a preliminary double-blind placebo-controlled smoking reduction study. Drug and Alcohol Dependence 2009, 103:30-36.
109. B receptor ligands in animal tests of depression and anxiety. Pharmacological Reports 2007, 59:645-655.
110. B receptor ligands on the immobility, swimming and climbing in the forced swim test in rats following discontinuation of cocaine self-administration. European Journal of Pharmacology 2010, 627:142-149.
111. B receptors. Neuropharmacology 1999, 38:1641-1646.
112. B receptors. Farmaco 2003, 58:173-183.
113. B modulators. The GABA receptors 2007, 239-251. Humana Press, Totowa, NJ. 3rd ed. S.J. Enna, H. Möhler (Eds.).
114. B receptor antagonist in clinical trials. Biochemical Pharmacology 2004, 68:1479-1487.
115. B modulators. The GABA receptors 1997, 271-296. Humana Press, Totowa, NJ. 2nd ed. S.J. Enna, N.G. Bowery (Eds.).
116. B agonists. Journal of Medicinal Chemistry 1995, 38:3297-3312.
117. B receptor antagonists. Pharmacology Reviews and Communications 1996, 8:127-133.
118. B antagonists. Journal of Medicinal Chemistry 1995, 38:3313-3331.
119. Fromm G.H. Baclofen as an adjuvant analgesic. Journal of Pain and Symptom Management 1994, 9:500-509.
120. Fromm G.H., Terrence C.F. Comparison of l-baclofen and racemic baclofen in trigeminal neuralgia. Neurology 1987, 37:1725-1728.
121. Fromm G.H., Terrence C.F., Chattha A.S. Baclofen in the treatment of trigeminal neuralgia: Double-blind study and long-term follow-up. Annals of neurology 1984, 15:240-244.
122. Fromm G.H., Terrence C.F., Chattha A.S., et al. Baclofen in trigeminal neuralgia: Its effect on the spinal trigeminal nucleus: A pilot study. Archives of Neurology 1980, 37:768-771.
123. Frost F., Nanninga J., Penn R., et al. Intrathecal baclofen infusion. Effect on bladder management programs in patients with myelopathy. American Journal of Physical Medicine & Rehabilitation 1989, 68:112-115.
124. Frydenvang K., Enna S.J., Krogsgaard-Larsen P. (-)-(R)-5,5-dimethylmorpholinyl-2-acetic acid ethyl ester hydrochloride. Acta Crystallographica 1997, C53:1088-1091.
125. B antagonists: Resolution, absolute stereochemistry, and pharmacology of (R)- and (S)-phaclofen. Chirality 1994, 6:583-589.
126. B receptors in peripheral nociceptors in vivo. Molecular Pain 2009, 5:68.
127. Gemignani A., Paudice P., Bonanno G., Raiteri M. Pharmacological discrimination between γ-aminobutyric acid type B receptors regulating cholecystokinin and somatostatin release from rat neocortex synaptosomes. Molecular Pharmacology 1994, 46:558-562.
128. B antagonist CGP 36742 prevents PTZ-kindling-provoked amnesia in rats. European Neuropsychopharmacology 2000, 10:273-278.
129. B receptor antagonists in an active avoidance learning paradigm in rats. Psychopharmacology 1998, 137:369-373.
130. B receptor antagonists on learning and memory retention in a rat model of absence epilepsy. European Journal of Pharmacology 1997, 320:9-13.
131. B receptor antagonists on active and passive avoidance responding in rodents with γ-hydroxybutyrolactone-induced absence syndrome. Psychopharmacology 2001, 157:89-95.
132. B receptor antagonists CGP63360, CGP76290A and CGP76291A on learning and memory processes in rodents. Central European Journal of Medicine 2007, 2:280-293.
133. Gianino J.M., York M.M., Paice J.A., et al. Quality of life: Effect of reduced spasticity from intrathecal baclofen. Journal of Neuroscience Nursing 1998, 30:47-54.
134. Giesser B. Multiple sclerosis. Current concepts in management. Drugs 1985, 29:88-95.
135. B receptors is altered after repeated amphetamine treatment. Neuroscience 2002, 109:585-595.
136. B receptor-mediated inhibition of cyclic AMP formation in rat striatum in vivo. Journal of Neurochemistry 2006, 96:1416-1422.
137. B receptor desensitization. Neuropharmacology 2008, 55:1293-1299.
138. B receptor ligands after a continuous, desensitizing agonist pretreatment. European Journal of Pharmacology 2009, 603:37-41.
139. Goodwin A.K., Froestl W., Weerts E.M. Involvement of γ-hydroxybutyrate (GHB) and GABA-B receptors in the acute behavioral effects of GHB in baboons. Psychopharmacology 2005, 180:342-351.
140. Goodwin A.K., Griffiths R.R., Brown P.R., et al. Chronic intragastric administration of γ-butyrolactone produces physical dependence in baboons. Psychopharmacology 2006, 189:71-82.
141. B agonist baclofen on bronchial hyperreactivity to inhaled histamine in subjects with cervical spinal cord injury. Lung 1997, 175:333-341.
142. Guelaud C., Similowski T., Bizec J.L., et al. Baclofen therapy for chronic hiccup. European Respiratory Journal 1995, 8:235-237.
143. B receptors. Bioorganic & Medicinal Chemistry Letters 2007, 17:6206-6211.
144. Gupta M., Greven R., Jansen E.E., et al. Therapeutic intervention in mice deficient for succinate semialdehyde dehydrogenase (γ-hydroxybutyric aciduria). Journal of Pharmacology and Experimental Therapeutics 2002, 302:180-187.
145. Hall R.G., Kane P.D., Bittiger H., Froestl W. Phosphinic acid analogues of γ-aminobutyric acid (GABA). Synthesis of a new radioligand. Journal of Labelled Compounds & Radiopharmaceuticals 1995, 36:129-135.
146. Haney M., Hart C.L., Foltin R.W. Effects of baclofen on cocaine self-administration: Opioid- and nonopioid-dependent volunteers. Neuropsychopharmacology 2006, 31:1814-1821.
147. B receptor antagonists elevate both mRNA and protein levels of the neurotrophins nerve growth factor (NGF) and brain-derived neurotrophic factor (BDNF) but not neurotrophin-3 (NT-3) in brain and spinal cord of rats. Neuropharmacology 2000, 39:449-462.
148. Heinrichs S.C., Leite-Morris K.A., Carey R.J., et al. Baclofen enhances extinction of opiate conditioned place preference. Behavioural Brain Research 2010, 207:353-359.
149. B receptor antagonist SGS742 improves spatial memory and reduces protein binding to the cAMP response element (CRE) in the hippocampus. Neuropharmacology 2005, 48:956-964.
150. Hering-Hanit R. Baclofen for prevention of migraine. Cephalalgia 1999, 19:589-591.
151. Hering-Hanit R., Gadoth N. Baclofen in cluster headache. Headache 2000, 40:48-51.
152. Hering-Hanit R., Gadoth N. The use of baclofen in cluster headache. Current Pain and Headache Reports 2001, 5:79-82.
153. B sites in rat brain. Nature 1981, 290(5802):149-152.
154. C receptors. Bioorganic & Medicinal Chemistry Letters 2008, 18:402-404.
155. Hog S., Wellendorph P., Nielsen B., et al. Novel high-affinity and selective biaromatic 4-substituted γ-hydroxybutyric acid (GHB) analogues as GHB ligands: Design, synthesis, and binding studies. Journal of Medicinal Chemistry 2008, 51:8088-8095.
156. Hogema B.M., Gupta M., Senephansiri H., et al. Pharmacologic rescue of lethal seizures in mice deficient in succinate semialdehyde dehydrogenase. Nature Genetics 2001, 29:212-216.
157. Hollmann M., O'Shea-Greenfield A., Rogers S.W., Heinemann S. Cloning by functional expression of a member of the glutamate receptor family. Nature 1989, 342:643-648.
158. B , receptor agonist. Alcoholism, Clinical and Experimental Research 2009, 33:108-120.
159. Hosford D.A., Wang Y., Liu C.C., Snead O.C. Characterization of the antiabsence effects of SCH 50911, a GABA-B receptor antagonist, in the lethargic mouse, γ-hydroxybutyrate, and pentylenetetrazole models. Journal of Pharmacology and Experimental Therapeutics 1995, 274:1399-1403.
160. Hotsenpiller G., Wolf M.E. Baclofen attenuates conditioned locomotion to cues associated with cocaine administration and stabilizes extracellular glutamate levels in rat nucleus accumbens. Neuroscience 2003, 118:123-134.
161. B receptor positive modulator CGP7930 in rodents. Neuropharmacology 2008, 54:854-862.
162. Jensen A.A., Mosbacher J., Elg S., et al. The anticonvulsant gabapentin (neurontin) does not act through gamma-aminobutyric acid-B receptors. Molecular Pharmacology 2002, 61:1377-1384.
163. Jingami H., Nakanishi S., Morikawa K. Structure of the metabotropic glutamate receptor. Current Opinion in Neurobiology 2003, 13:271-278.
164. John J.P., Sunyer B., Höger H., et al. Hippocampal synapsin isoform levels are linked to spatial memory enhancement by SGS742. Hippocampus 2009, 19:731-738.
165. Kahn R., Biswas K., Childress A.R., et al. Multi-center trial of
166. B receptor antagonists and their interaction in rats with a genetic form of absence epilepsy. European Journal of Pharmacology 2001, 430:251-259.
167. B receptors, schizophrenia and sleep dysfunction: A review of the relationship and its potential clinical and therapeutic implications. CNS Drugs 2009, 23:681-691.
168. Kaplan G.B., McRoberts R.L., Smokler H.J. Baclofen as adjunctive treatment for a patient with cocaine dependence and schizoaffective disorder. Journal of Clinical Psychopharmacology 2004, 24:574-575.
169. B receptors, receptor-specific ligands and their uses 1997, WO 97/46675; Publ. date: 11 Dec 1997, Priority: 30 May 1996 for Novartis AG.
170. B1 -deficient mice. European Journal of Neuroscience 2003, 18:2722-2730.
171. B receptors. Embryonic Encyclopedia of Life Sciences 2001, Nature Publishing Group, London. http://www.els.net.
172. B receptors uncovers similarity to metabotropic glutamate receptors. Nature 1997, 386:239-246.
173. B2 subunits. Journal of Pharmacological Sciences 2004, 94:368-375.
174. Keberle H., Faigle J.W., Wilhelm M. Procedure for the preparation of new aminioacids. Swiss Patent 449046, Publ. date: 11 Apr 1968; Priority: 09 Jul 1963, Chem Abstr. 1968, 69:106273f.
175. 3 H]CGP 62349. Brain Research. Molecular Brain Research 1999, 71:279-289.
176. B receptor antagonist in central and peripheral preparations. European Journal of Pharmacology 1995, 287:185-189.
177. B receptors. Neuroscience Letters 1988, 92:92-96.
178. Kerr D.I., Ong J., Prager R.H., et al. Phaclofen: A peripheral and central baclofen antagonist. Brain Research 1987, 405:150-154.
179. Kirmse K., Kirischuk S., Grantyn R. Role of GABA transporter 3 in GABAergic synaptic transmission at striatal output neurons. Synapse 2009, 63:921-929.
180. Knapp D.J., Overstreet D.H., Breese G.R. Baclofen blocks expression and sensitization of anxiety-like behavior in an animal model of repeated stress and ethanol withdrawal. Alcoholism, Clinical and Experimental Research 2007, 31:582-595.
181. B agonist baclofen in patients with symptoms and duodeno-gastro-oesophageal reflux refractory to proton pump inhibitors. Gut 2003, 52:1397-1402.
182. Krach L.E. Intrathecal baclofen use in adults with cerebral palsy. Developmental Medicine and Child Neurology 2009, 51(Suppl. 4):106-112.
183. Kroin J.S. Intrathecal drug administration. Present use and future trends. Clinical Pharmacokinetics 1992, 22:319-326.
184. Kubo T., Fukuda K., Mikami A., et al. Cloning, sequencing and expression of complementary DNA encoding the muscarinic acetylcholine receptor. Nature 1986, 323:411-416.
185. Kunishima N., Shimada Y., Tsuji Y., et al. Structural basis of glutamate recognition by a dimeric metabotropic glutamate receptor. Nature 2000, 407:971-977.
186. Lal R., Sukbuntherng J., Tai E.H., et al. Arbaclofen placarbil, a novel R-baclofen prodrug: Improved absorption, distribution, metabolism, and elimination properties compared with R-baclofen. Journal of Pharmacology and Experimental Therapeutics 2009, 330:911-921.
187. B receptor agonist. Neuropharmacology 2001, 41:965-975.
188. Lapin I. Phenibut (beta-phenyl-GABA): A tranquilizer and nootropic drug. CNS Drug Reviews 2001, 7:471-481.
189. B receptors completely reverses age-related learning impairment. Neuroscience 2009, 164:941-947.
190. Le Foll B., Wertheim C.E., Goldberg S.R. Effects of baclofen on conditioned rewarding and discriminative stimulus effects of nicotine in rats. Neuroscience Letters 2008, 443:236-240.
191. Leggio L. Understanding and treating alcohol craving and dependence: Recent pharmacological and neuroendocrinological findings. Alcohol and Alcoholism 2009, 44:341-352.
192. Lehmann A. Novel treatments of GERD: Focus on the lower esophageal sphincter. European Review for Medical and Pharmacological Sciences 2008, 12(Suppl. 1):103-110.
193. B receptors as drug targets to treat gastroesophageal reflux disease. Pharmacology & Therapeutics 2009, 122:239-245.
194. B receptor inhibits transient lower esophageal sphincter relaxations in dogs. Gastroenterology 1999, 117:1147-1154.
195. B receptor agonist, inhibits transient lower esophageal sphincter relaxation through a peripheral mode of action. Journal of Pharmacology and Experimental Therapeutics 2009, 331:504-512.
196. Lehmann A., Hansson-Branden L., Karrberg L. Effects of repeated administration of baclofen on transient lower esophageal sphincter relaxation in the dog. European Journal of Pharmacology 2000, 403:163-167.
197. Leisen C., Langguth P., Herbert B., et al. Lipophilicities of baclofen ester prodrugs correlate with affinities to the ATP-dependent efflux pump P-glycoprotein: Relevance for their permeation across the blood-brain barrier?. Pharmaceutical Research 2003, 20:772-778.
198. B receptor activation in the ventral tegmental area inhibits the acquisition and expression of opiate-induced motor sensitization. Journal of Pharmacology and Experimental Therapeutics 2004, 308:667-678.
199. B receptors inhibit backpropagating dendritic spikes in hippocampal CA1 pyramidal cells in vivo. Hippocampus 2006, 16:388-407.
200. Leung L.S., Peloquin P., Canning K.J. Paired-pulse depression of excitatory postsynaptic current sinks in hippocampal CA1 in vivo. Hippocampus 2008, 18:1008-1020.
201. B receptor blockade enhances theta and gamma rhythms in the hippocampus of behaving rats. Hippocampus 2007, 17:281-291.
202. Levin E.D., Weber E., Icenogle L. Baclofen interactions with nicotine in rats: Effects on memory. Pharmacology, Biochemistry, and Behavior 2004, 79:343-348.
203. B receptor-positive modulation decreases selective molecular and behavioral effects of cocaine. Neuropsychopharmacology 2007, 32:388-398.
204. B ) receptors on living cells: Design, synthesis, and biological evaluation. Journal of Medicinal Chemistry 2008, 51:3057-3060.
205. B receptor allosteric modulator CGP7930, like baclofen, reduces operant self-administration of ethanol in alcohol-preferring rats. Neuropharmacology 2006, 50:632-639.
206. B agonist baclofen in normal subjects. Gastroenterology 2000, 118:7-13.
207. Lile J.A., Stoops W.W., Allen T.S., et al. Baclofen does not alter the reinforcing, subject-rated or cardiovascular effects of intranasal cocaine in humans. Psychopharmacology 2004, 171:441-449.
208. Ling W., Shoptaw S., Majewska D. Baclofen as a cocaine anti-craving medication: A preliminary clinical study. Neuropsychopharmacology 1998, 18:403-404.
209. B receptors. Neuropharmacology 1999, 38:1667-1673.
210. 1C receptor by electrophysiological assays of mRNA-injected Xenopus oocytes. Proceedings of the National Academy of Sciences of the United States of America 1987, 84:4332-4336.
211. B receptor agonist and antagonists decreased brain stimulation reward in the rat. Neuropharmacology 2001, 40:676-685.
212. Maccioni P., Bienkowski P., Carai M.A., et al. Baclofen attenuates cue-induced reinstatement of alcohol-seeking behavior in Sardinian alcohol-preferring (sP) rats. Drug and Alcohol Dependence 2008, 95:284-287.
213. B receptor, BHF177, in alcohol-preferring rats. Alcoholism, Clinical and Experimental Research 2009, 33:1749-1756.
214. B receptor direct agonist, baclofen. Alcoholism, Clinical and Experimental Research 2008, 32:1558-1564.
215. B receptor, GS39783, on alcohol self-administration in alcohol-preferring rats. Psychopharmacology 2007, 193:171-178.
216. Maccioni P., Serra S., Vacca G., et al. Baclofen-induced reduction of alcohol reinforcement in alcohol-preferring rats. Alcohol 2005, 36:161-168.
217. B receptors. Molecular and Cellular Neurosciences 2008, 37:599-609.
218. B receptors in Schwann cells influence proliferation and myelin protein expression. European Journal of Neuroscience 2004, 19:2641-2649.
219. B receptors. British Journal of Pharmacology 2008, 154:797-811.
220. B receptors 2005, US 2005/0197337 A1; Publ. date: 08 Sep 2005, Priority: EP2004-100830, 02 Mar 2004, for Hoffmann-La Roche Inc.
221. Manning J.P., Richards D.A., Bowery N.G. Pharmacology of absence epilepsy. Trends in Pharmacological Sciences 2003, 24:542-549.
222. B receptor coupling in rat brain: A scintillation proximity assay characterisation of G protein subtypes. Journal of Neurochemistry 2008, 105:308-323.
223. Mares P., Kubova H. What is the role of neurotransmitter systems in cortical seizures?. Physiological Research 2008, 57(Suppl. 3):S111-S120.
224. B antagonist in two models of epileptic seizures in developing rats. Brain Research Bulletin 2006, 71:160-166.
225. Markou A. Neurobiology of nicotine dependence. Philosophical Transactions of the Royal Society of London. Series B, Biological Sciences 2008, 363(1507):3159-3168.
226. Markou A., Paterson N.E., Semenova S. Role of γ-aminobutyric acid (GABA) and metabotropic glutamate receptors in nicotine reinforcement: Potential pharmacotherapies for smoking cessation. Annals of the New York Academy of Sciences 2004, 1025:491-503.
227. B heterodimer a good drug target?. Journal of Molecular Neuroscience 2005, 26:169-176.
228. Masu M., Tanabe Y., Tsuchida K., et al. Sequence and expression of a metabotropic glutamate receptor. Nature 1991, 349:760-765.
229. B receptor agonist. European Journal of Pharmacology 1997, 321:67-75.
230. B receptor function and subunit expression in the rat spinal cord as indicators of stress and the antinociceptive response to antidepressants. Brain Research 2006, 1068:109-117.
231. B receptor expression and function in an animal model of neuropathic pain. Biochemical Pharmacology 2005, 71:196-202.
232. Miller F., Korsvik H. Baclofen in the treatment of stiff-man syndrome. Annals of Neurology 1981, 9(5):511-512.
233. B receptors in the modulation of anxiety- and antidepressant-like behavior. Neuropsychopharmacology 2004, 29:1050-1062.
234. B receptor-positive modulation-induced blockade of the rewarding properties of nicotine is associated with a reduction in nucleus accumbens DeltaFosB accumulation. Journal of Pharmacology and Experimental Therapeutics 2007, 321:172-177.
235. Moriyoshi K., Masu M., Ishii T., et al. Molecular cloning and characterization of the rat NMDA receptor. Nature 1991, 354:31-37.
236. Moutoussis M., Orrell W. Baclofen therapy for rigidity associated with Lewy body dementia. British Journal of Psychiatry 1996, 169:795.
237. Müller H., Borner U., Zierski J., et al. Intrathecal baclofen for treatment of tetanus-induced spasticity. Anesthesiology 1987, 66:76-79.
238. B receptor antagonist CGP36742 improves learned helplessness in rats. European Journal of Pharmacology 1999, 381:1-7.
239. B receptor antagonist CGP36742 attenuates the baclofen- and scopolamine-induced deficit in Morris water maze task in rats. Brain Research 1997, 766:101-106.
240. Nanninga J.B., Frost F., Penn R. Effect of intrathecal baclofen on bladder and sphincter function. Journal of Urology 1989, 142:101-105.
241. Ng G.Y., Bertrand S., Sullivan R., et al. Gamma-aminobutyric acid type B receptors with specific heterodimer composition and postsynaptic actions in hippocampal neurons are targets of anticonvulsant gabapentin action. Molecular Pharmacology 2001, 59:144-152.
242. B receptors. Biochemical Pharmacology 2004, 68:1667-1674.
243. B receptor antagonists, in rodents. British Journal of Pharmacology 2006, 149:581-590.
244. B receptor antagonist CGP-36742 enhances somatostatin release in the rat hippocampus in vivo and in vitro. European Journal of Pharmacology 2003, 478(2-3):111-119.
245. O'Brien C.F., Seeberger L.C., Smith D.B. Spasticity after stroke. Epidemiology and optimal treatment. Drugs Aging 1996, 9:332-340.
246. Ochs G., Struppler A., Meyerson B.A., et al. Intrathecal baclofen for long-term treatment of spasticity: A multi-centre study. Journal of Neurology, Neurosurgery, and Psychiatry 1989, 52:933-939.
247. Ochs G.A. Intrathecal baclofen. Bailliére's Clinical Neurology 1993, 2:73-86.
248. B receptor function in human frontal cortex. Neurochemistry International 2005, 46:149-158.
249. Olpe H.R., Demieville H., Baltzer V., et al. The biological activity of d- and l-baclofen (Lioresal). European Journal of Pharmacology 1978, 52:133-136.
250. B receptors. European Journal of Pharmacology 1990, 187:27-38.
251. Omari T.I., Benninga M.A., Sansom L., et al. Effect of baclofen on esophagogastric motility and gastroesophageal reflux in children with gastroesophageal reflux disease: A randomized controlled trial. Journal of Pediatrics 2006, 149:468-474.
252. B receptors dually coupled to cyclic AMP by the allosteric agent CGP7930. European Journal of Pharmacology 2003, 471:77-84.
253. B receptor agonists CGP 44532 and 44533 in central and peripheral tissues. European Journal of Pharmacology 2001, 412:27-37.
254. B presynaptic receptors in rat brain. European Journal of Pharmacology 2001, 415:191-195.
255. B receptors in brain slices but a partial agonist in the ileum. European Journal of Pharmacology 1993, 233:169-172.
256. B receptor, CGP7930 and GS39783, on alcohol intake in alcohol-preferring rats. European Journal of Pharmacology 2005, 525:105-111.
257. B receptor-mediated signaling reduces the susceptibility of fragile X knockout mice to audiogenic seizures. Molecular Pharmacology 2009, 76:18-24.
258. B autoreceptors. Clinical and Experimental Pharmacology & Physiology 2008, 35:1113-1115.
259. B heteroreceptors in rat cortical slices. European Journal of Pharmacology 2004, 495:137-143.
260. B receptor ligands in rodent tests of anxiety-like behavior. Pharmacological Reports 2007, 59:757-762.
261. B agonists and gabapentin on mechanical hyperalgesia in models of neuropathic and inflammatory pain in rats. Pain 2001, 90:217-226.
262. B receptor-mediated regulation of brain reward function. Neuropharmacology 2005, 49:953-962.
263. B receptor agonists baclofen and CGP44532 decreased nicotine self-administration in the rat. Psychopharmacology 2004, 172:179-186.
264. B receptor agonist CGP44532 decreased nicotine self-administration, and acute administration decreased cue-induced reinstatement of nicotine-seeking in rats. Neuropsychopharmacology 2005, 30:119-128.
265. B receptors decreased nicotine self-administration and counteracted nicotine-induced enhancement of brain reward function in rats. Journal of Pharmacology and Experimental Therapeutics 2008, 326:306-314.
266. Penn R.D., Kroin J.S. Intrathecal baclofen alleviates spinal cord spasticity. Lancet 1984, 323(8385):1078.
267. Penn R.D., Kroin J.S. Continuous intrathecal baclofen for severe spasticity. Lancet 1985, 326(8447):125-127.
268. Penn R.D., Kroin J.S. Long-term intrathecal baclofen infusion for treatment of spasticity. Journal of Neurosurgery 1987, 66:181-185.
269. B receptor antagonist SCH 50,911. European Journal of Pharmacology 2005, 515:94-98.
270. Pilc A., Lloyd K.G. Chronic antidepressants and GABA "B" receptors: A GABA hypothesis of antidepressant drug action. Life Sciences 1984, 35:2149-2154.
271. B receptors. Drugs Today 2005, 41:755-766.
272. B receptor. Biochemical Pharmacology 2004, 68:1565-1572.
273. B receptors: Mechanism of action and therapeutic perspective. Current Neuropharmacology 2007, 5:195-201.
274. B receptor antagonists. Neuropharmacology 2001, 41:301-310.
275. B receptors at inhibitory synapses in the CA1 region of the rat hippocampus. British Journal of Pharmacology 1999, 127:211-219.
276. Prager R.H., Schafer K., Hamon D.P., et al. The synthesis of (R)-(-) and (S)-(+)-hydroxy-saclofen. Tetrahedron 1995, 51:11465-11472.
277. Prakash Y.S. Gamma-aminobutyric acid: Something old, something new for bronchodilation. Anesthesiology 2009, 110:696-697.
278. B receptor binding sites in rat frontal cortex. British Journal of Pharmacology 1993, 110:724-735.
279. 3 H]-CGP62349 in hippocampus resected from patients with temporal lobe epilepsy. British Journal of Pharmacology 2002, 136:1099-1106.
280. B2 receptor subunits in the somatosensory cerebral cortex and thalamus of rats with absence seizures (GAERS). Epilepsy Research 2003, 55:39-51.
281. B inhibitory postsynaptic currents in the rat hippocampus. Neurobiology of Disease 2010, 37:704-710.
282. B receptors. Handbook of Experimental Pharmacology 2008, 184:373-407.
283. Rapidi C.A., Panourias I.G., Petropoulou K., et al. Management and rehabilitation of neuropathic bladder in patients with spinal cord lesion. Acta Neurochirurgica. Supplement 2007, 97(Pt 1):307-314.
284. Rawlins P. Patient management of cerebral origin spasticity with intrathecal baclofen. Journal of Neuroscience Nursing 1998, 30(1):32-35. and 40-46.
285. B receptor activation in mouse frontal cortex and hippocampus. Journal of Biological Chemistry 2003, 278:42006-42011.
286. B receptors and cAMP-dependent protein kinase activation. Neuroscience 2006, 141:269-275.
287. B receptor agonist in the locus coeruleus of rats. Behavioural Brain Research 2009, 196:11-14.
288. B antagonist, SCH50911, in the genetic absence epilepsy rat of Strasbourg (GAERS). Pharmacology Reviews and Communications 1996, 8:227-230.
289. B presynaptic receptors modulate glycine exocytosis from mouse spinal cord and hippocampus glycinergic nerve endings. Pharmacological Research 2009, 59:154-159.
290. Rotheram-Fuller E., De la Garza R., Mahoney J.J., et al. Subjective and cardiovascular effects of cocaine during treatment with amantadine and baclofen in combination. Psychiatry Research 2007, 152:205-210.
291. B receptors within the ventral tegmental area are involved in the expression and acquisition of morphine-induced place preference in morphine-sensitized rats. Pharmacology, Biochemistry, and Behavior 2009, 91:409-416.
292. B receptor function and subunit expression in rat hippocampus. Biochemical Pharmacology 2004, 68:1489-1495.
293. + -evoked release of sensory CGRP from the guinea pig urinary bladder. Life Sciences 1991, 48:L69-L72.
294. Santos M.L., Mota-Miranda A., Alves-Pereira A., et al. Intrathecal baclofen for the treatment of tetanus. Clinical Infectious Diseases 2004, 38(3):321-328.
295. Sawynok J., Dickson C. d-Baclofen: Is it an antagonist at baclofen receptors?. Progress in Neuro-psychopharmacology & Biological Psychiatry 1984, 8:729-731.
296. Sawynok J., Dickson C. d-Baclofen is an antagonist at baclofen receptors mediating antinociception in the spinal cord. Pharmacology 1985, 31:248-259.
297. Scheinberg A., Hall K., Lam L.T., et al. Oral baclofen in children with cerebral palsy: A double-blind cross-over pilot study. Journal of Paediatrics and Child Health 2006, 42:715-720.
298. A receptor shows a ligand-gated receptor super-family. Nature 1987, 328:221-227.
299. + channels, through GTP-binding proteins. Brain Research. Molecular Brain Research 1990, 8:301-309.
300. B receptors do not mediate the inhibitory actions of gabapentin on spinal reflexes in rats. Journal of Pharmacological Sciences 2004, 96:444-449.
301. Shoptaw S., Yang X., Rotheram-Fuller E.J., et al. Randomized placebo-controlled trial of baclofen for cocaine dependence: Preliminary effects for individuals with chronic patterns of cocaine use. Journal of Clinical Psychiatry 2003, 64:1440-1448.
302. Silbert P.L., Matsumoto J.Y., McManis P.G., et al. Intrathecal baclofen therapy in stiff-man syndrome: A double-blind, placebo-controlled trial. Neurology 1995, 45:1893-1897.
303. B receptors in depression and antidepressant-related behavioural responses. Drug Development Research 2006, 67:477-494.
304. B receptor antagonist-mediated antidepressant-like behavior is serotonin-dependent. Journal of Pharmacology and Experimental Therapeutics 2005, 312:290-296.
305. B receptor agonist baclofen attenuate the reward-facilitating effects of cocaine: Intercranial self-stimulation studies in the rat. Neuropsychopharmacology 2005, 30:2065-2072.
306. B (R1) receptors in the rat hippocampus by immunocytochemistry and high resolution autoradiography, with specific reference to its localization in identified hippocampal interneuron subpopulations. Neuropharmacology 1999, 38:1707-1721.
307. Smith C.R., LaRocca N.G., Giesser B.S., et al. High-dose oral baclofen: Experience in patients with multiple sclerosis. Neurology 1991, 41:1829-1831.
308. B receptor on cocaine self-administration in rats. Psychopharmacology 2004, 173:105-111.
309. B receptor agonist baclofen prevents heroin-induced reinstatement of heroin-seeking behavior in rats. Neuropharmacology 2007, 52:1555-1562.
310. Stayer C., Tronnier V., Dressnandt J., et al. Intrathecal baclofen therapy for stiff-man syndrome and progressive encephalomyelopathy with rigidity and myoclonus. Neurology 1997, 49:1591-1597.
311. B receptor receptor activation. Epilepsy Research 1999, 33:169-176.
312. Sunyer B., Diao W.F., Kang S.U., et al. Cognitive enhancement by SGS742 in OF1 mice is linked to specific hippocampal protein expression. Journal of Proteome Research 2008, 7:5237-5253.
313. Sunyer B., Patil S., Frischer C., et al. Strain-dependent effects of SGS742 in the mouse. Behavioural Brain Research 2007, 181:64-75.
314. Sunyer B., Shim K.S., An G., et al. Hippocampal levels of phosphorylated protein kinase A (phosphor-S96) are linked to spatial memory enhancement by SGS742. Hippocampus 2009, 19:90-98.
315. Sunyer B., Shim K.S., Höger H., Lubec G. The cognitive enhancer SGS742 does not involve major known signaling cascades in OF1 mice. Neurochemical Research 2008, 33:1384-1392.
316. B receptor in Xenopus oocytes and inhibition of the response by activation of protein kinase C. FEBS Letters 1991, 278:222-224.
317. Taylor M.C., Bates C.P. A double-blind crossover trial of baclofen-a new treatment for the unstable bladder syndrome. British Journal of Urology 1979, 51:504-505.
318. B receptors in tissues from pharmacoresistant epilepsy patients. Epilepsia 2009, 50:1697-1716.
319. Terrence C.F., Sax M., Fromm G.H., et al. Effect of baclofen enantiomorphs on the spinal trigeminal nucleus and steric similarities of carbamazepine. Pharmacology 1983, 27:85-94.
320. B receptor antagonist ligand: Radiosynthesis and PET studies in monkeys. Journal of Labelled Compounds & Radiopharmaceuticals 1997, 40:651-652.
321. B receptor antagonist. Nuclear Medicine and Biology 2000, 27:565-569.
322. B receptor antagonist improves cognition in patients with mild cognitive impairment. Meeting of the American Association of Neurology 2004, San Francisco, April 27, Poster Po 2.053.
323. B receptor-mediated-ERK1/2/CREB pathway in cerebellar neurons. Cellular Signalling 2007, 19:1996-2002.
324. B receptor activation protects neurons from apoptosis via IGF-1 receptor transactivation. Journal of Neuroscience 2010, 30:749-759.
325. Turkyilmaz A., Eroglu A. Use of baclofen in the treatment of esophageal stent-related hiccups. Annals of Thoracic Surgery 2008, 85:328-330.
326. Twycross R. Baclofen for hiccups. American Journal of Hospice & Palliative Care 2003, 20:262.
327. B -receptor subtypes in the thalamus. Journal of Neurophysiology 2007, 98:3791-3795.
328. B receptors. Allosteric Receptor Modulation in Drug Targeting 2006, 235-258. Informa Healthcare (Taylor & Francis), New York, NY. N.G. Bowery (Ed.).
329. B receptors by CGP7930 and GS39783: Effects on affinities and efficacies of orthosteric ligands with distinct intrinsic properties. Neuropharmacology 2005, 48:343-353.
330. B receptors by. 2,6-di-tert.-butyl-4-(3-hydroxy-2,2-di-methyl-propyl)-phenol (CGP7930) and its aldehyde analogue CGP13501. Molecular Pharmacology 2001, 60:963-971.
331. Urwyler S., Pozza M.F., Lingenhoehl K., et al. N,N'-dicyclopentyl-2-methylsulfanyl-5-nitro-pyrimidine-4,6-diamine (GS39783) and structurally related compounds: Novel allosteric enhancers
332. van Bree J.B., Audus K.L., Borchardt R.T. Carrier-mediated transport of baclofen across monolayers of bovine brain endothelial cells in primary culture. Pharmaceutical Research 1988, 5:369-371.
333. van Bree J.B., Heijligers-Feijen C.D., De Boer A.G., et al. Stereoselective transport of baclofen across the blood-brain barrier in rats as determined by the unit impulse response methodology. Pharmaceutical Research 1991, 8:259-262.
334. van Herwaarden M.A., Samsom M., Rydholm H., et al. The effect of baclofen on gastro-oesophageal reflux, lower oesophageal sphincter function and reflux symptoms in patients with reflux disease. Alimentary Pharmacology & Therapeutics 2002, 16:1655-1662.
335. B receptor antagonists on absences and convulsive seizures. European Journal of Pharmacology 1997, 332:245-255.
336. B antagonist, CGP 35348, antagonizes the effects of baclofen, γ-butyrolactone and HA 966 on rat striatal dopamine synthesis. Naunyn-Schmiedeberg's Archives of Pharmacology 1991, 343:173-178.
337. Weerts E.M., Froestl W., Griffiths R.R. Effects of GABAergic modulators on food and cocaine self-administration in baboons. Drug and Alcohol Dependence 2005, 80:369-376.
338. Weerts E.M., Goodwin A.K., Griffiths R.R., et al. Spontaneous and precipitated withdrawal after chronic intragastric administration of γ-hydroxybutyrate (GHB) in baboons. Psychopharmacology 2005, 179:678-687.
339. B receptor agonists baclofen and CGP44532 but not the GABA reuptake inhibitor tiagabine in baboons. Drug and Alcohol Dependence 2007, 89:206-213.
340. Wellendorph P., Hog S., Greenwood J.R., et al. Novel cyclic γ-hydroxybutyrate (GHB) analogs with high affinity and stereoselectivity of binding to GHB sites in rat brain. Journal of Pharmacology and Experimental Therapeutics 2005, 315:346-351.
341. Wellendorph P., Hog S., Skonberg C., Bräuner-Osborne H. Phenylacetic acids and the structurally related non-steroidal anti-inflammatory drug diclofenac bind to specific γ-hydroxybutyric acid sites in rat brain. Fundamental & Clinical Pharmacology 2009, 23:207-213.
342. Whelan J.L. Baclofen in treatment of the "stiff-man" syndrome. Archives of Neurology 1980, 37:600-601.
343. B receptor in mice. British Journal of Pharmacology 2010, (in press).
344. Wong C.G., Gibson K.M., Snead O.C. From the street to the brain: Neurobiology of the recreational drug γ-hydroxybutyric acid. Trends in Pharmacological Sciences 2004, 25:29-34.
345. B receptors. Brain Research. Molecular Brain Research 1992, 16:204-210.
346. Xi Z.X., Stein E.A. Baclofen inhibits heroin self-administration behavior and mesolimbic dopamine release. Journal of Pharmacology and Experimental Therapeutics 1999, 290:369-1374.
347. B receptors in wild type and weaver hippocampus "in. vitro." Epilepsy Research 2003, 52:263-273.
348. Zarrindast M.R., Hoghooghi V., Rezayof A. Inhibition of morphine-induced amnesia in morphine-sensitized mice: Involvement of dorsal hippocampal GABAergic receptors. Neuropharmacology 2008, 54:569-576.
349. B agonist baclofen in patients with gastro-oesophageal reflux disease. Gut 2002, 50:19-24.
350. B receptor function in the offspring. Journal of Pharmacology and Experimental Therapeutics 2008, 327:820-826.